A recent survey of women in the Netherlands found that 79 percent of respondents diagnosed with breast cancer noticed symptoms prior to being diagnosed.
Multiple Publications and Presentations Throughout 2018 Substantially Strengthen the Body of Evidence Emphasizing the Economic Costs of Unnecessary Breast Biopsies and the Power of the Imagio® Breast Imaging System
1/8/19: "Multiple publications and presentations over the course of 2018 substantially strengthen the body of evidence emphasizing the economic costs of unnecessary breast biopsies and the power of our Imagio® Breast Imaging System to potentially reduce the number of these procedures," said Thomas Umbel, President and CEO of Seno Medical. "This growing evidence base further advances the compelling value proposition that Seno Medical offers to patients, physicians, and payers. We believe this robust body of evidence will help to position the Imagio system as a sound diagnostic tool for the breast imaging community. The selection of Imagio as a finalist for the 2018 Medtech Insight Awards in the 'Best Proof-of-Value of an Innovation' category demonstrates widespread recognition of our value proposition."
5/3/18: Publication in AJR defines advanced statistical methods that can be used with diagnostic imaging output to downgrade breast mass risk classification.
Seno Medical Instruments Investigator Speaking to Opto-Acoustic Breast Imaging as a Strong Predictor of Malignancy
Results Presented at the American Roentgen Ray Society (ARRS) Annual Meeting Seno Medical Instruments, Inc. (Seno Medical), the leader in new technology for breast cancer diagnosis, is using opto-acoustic (OA/US) imaging to differentiate benign from malignant masses. Seno...